Seattle Genetics (SGEN) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/01/23
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline ProgressBusiness Wire • 11/01/23
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/25/23
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 TrialBusiness Wire • 10/22/23
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder CancerPRNewsWire • 10/22/23
Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023Business Wire • 10/16/23
Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares JumpInvestopedia • 09/22/23
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By PfizerInvestors Business Daily • 09/22/23
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 TrialPRNewsWire • 09/22/23
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment resultsMarket Watch • 09/05/23
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapyBusiness Wire • 09/04/23
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy AloneBusiness Wire • 09/04/23
Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report?Zacks Investment Research • 09/01/23
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast CancerBusiness Wire • 08/16/23